Sugi Predict

Sugi Predict / Compounds / SCHEMBL2454069

SCHEMBL2454069

SCHEMBL2454069

N[C@H](C(=O)O)C(O)c1ccco1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.60
▸ POLB P06746 2/20 0.60
▸ BLM P54132 2/20 0.60
▸ PTPN1 P18031 2/20 0.60
▸ PKM P14618 1/20 0.60
▸ PTPN7 P35236 1/20 0.60
▸ ESR2 Q92731 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ SLC1A3 P43003 2/20 0.47
▸ SLC1A2 P43004 2/20 0.47
▸ SLC1A1 P43005 2/20 0.47
▸ ALOX5 P09917 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ AGTR1 P30556 1/20 0.46
▸ CYP2C19 P33261 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ ADRA1A P35348 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2454068 1.00 KMT2A (0.60) KMT2APOLBBLMPTPN1PKM
SCHEMBL1085009 0.85 KMT2A (0.50) KMT2APOLBBLMPTPN1PKM
SCHEMBL18211553 0.83 KMT2A (0.50) KMT2APOLBBLMPTPN1PKM
SCHEMBL13374205 0.83 KMT2A (0.50) KMT2APOLBBLMPTPN1PKM
SCHEMBL14899622 0.79 KMT2A (0.44) KMT2APOLBBLMPTPN1PKM
SCHEMBL11151822 0.78 KMT2A (0.58) KMT2APOLBBLMPTPN1PKM
SCHEMBL15272327 0.78 KMT2A (0.58) KMT2APOLBBLMPTPN1PKM
SCHEMBL15272598 0.78 KMT2A (0.58) KMT2APOLBBLMPTPN1PKM
SCHEMBL2455073 0.78 KMT2A (0.61) KMT2APOLBBLMPTPN1PKM
SCHEMBL15049401 0.78 KMT2A (0.61) KMT2APOLBBLMPTPN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851119-B2 Boron-containing diacylhydrazines INTREXON CORPORATION (US) 2020-12-01 — — US disclosed
US-20200157122-A1 BORON-CONTAINING DIACYLHYDRAZINES INTREXON CORP (US) 2020-05-21 — — US disclosed
EP-3194359-B1 BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS INTREXON CORP (US) 2020-04-08 — — EP disclosed
US-10570158-B2 Boron-containing diacylhydrazine compounds INTREXON CORPORATION (US) 2020-02-25 — — US disclosed
US-10464951-B2 Boron-containing diacylhydrazines INTREXON CORPORATION (US) 2019-11-05 — — US disclosed
US-20180201628-A1 Boron-Containing Diacylhydrazine Compounds INTREXON CORP (US) 2018-07-19 — — US disclosed
EP-2970106-B1 BORON-CONTAINING DIACYLHYDRAZINES INTREXON CORP (US) 2018-05-16 — — EP disclosed
US-9944659-B2 Boron-containing diacylhydrazine compounds INTREXON CORPORATION (US) 2018-04-17 — — US disclosed
US-20180079759-A1 Boron-Containing Diacylhydrazines INTREXON CORPORATION (US) 2018-03-22 — — US disclosed
EP-3194359-A1 BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS Intrexon Corporation (US) 2017-07-26 — — EP disclosed
WO-2002013848-A1 HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS INVITROGEN CORPORATION (US) 2002-02-21 — — WO disclosed
CN-1297354-A Dipeptide caspase inhibitors and use thereof CYTOVIA INC (US) 2001-05-30 — — CN disclosed
WO-2001027140-A1 CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH CYTOVIA, INC. (US) 2001-04-19 — — WO disclosed
EP-1076563-A1 DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF Cytovia, Inc. (US) 2001-02-21 — — EP disclosed
US-6153591-A PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS CYTOVIA, INC. (US) 2000-11-28 — — US disclosed
WO-1999047154-A1 DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA, INC. (US) 1999-09-23 — — WO disclosed
EP-0460883-B1 Process for beta-hydroxy-alpha-amino acids UNIV NOTRE DAME DU LAC (US) 1997-01-15 — — EP disclosed
US-5266468-A Process for preparing β-hydroxy-α amino acids UNIVERSITY OF NOTRE DAME DU LAC (US) 1993-11-30 — — US disclosed
CN-1058046-A The method for preparing beta-hydroxy-a-amino acid UNIV NOTRE DAME DU LAC (US) 1992-01-22 — — CN disclosed
EP-0460883-A2 Process for beta-hydroxy-alpha-amino acids THE UNIVERSITY OF NOTRE DAME DU LAC (US) 1991-12-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464951-B2 Boron-containing diacylhydrazines CD22, BRDT, BCR KMT2A 1526/4885POLB 4516/4885BLM 1125/4885
US-20180201628-A1 Boron-Containing Diacylhydrazine Compounds BRDT, CD22, BCR KMT2A 1563/4885POLB 4603/4885BLM 1098/4885
US-10851119-B2 Boron-containing diacylhydrazines CD22, BRDT, BCR KMT2A 1526/4885POLB 4516/4885BLM 1125/4885
US-20200157122-A1 BORON-CONTAINING DIACYLHYDRAZINES CD22, BRDT, BCR KMT2A 1526/4885POLB 4516/4885BLM 1125/4885
US-10570158-B2 Boron-containing diacylhydrazine compounds BRDT, CD22, BCR KMT2A 1563/4885POLB 4603/4885BLM 1098/4885
US-20180079759-A1 Boron-Containing Diacylhydrazines CD22, BRDT, BCR KMT2A 1526/4885POLB 4516/4885BLM 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.